Pfizer Adjusts Evaluation Score Amid Strong Sales and Subdued Growth Outlook
Pfizer has recently adjusted its evaluation score, reflecting changes in technical trends. The company showcases strong management efficiency with a return on equity of 19.67% and reported record net sales of Rs 591.91 crore. However, long-term growth appears limited, with modest annual growth rates in net sales and operating profit.
Pfizer, a prominent player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation score. This revision reflects a shift in the technical trends associated with the stock, moving from a bullish stance to a mildly bullish outlook. Key financial metrics indicate that Pfizer has demonstrated strong management efficiency, highlighted by a return on equity (ROE) of 19.67%. The company reported its highest net sales for the quarter at Rs 591.91 crore, with an operating profit margin of 38.43%. Despite these positive indicators, the long-term growth trajectory appears subdued, with net sales growing at an annual rate of 1.18% and operating profit at 7.68% over the past five years.
The stock is currently trading at a premium compared to its peers, with a price-to-book value of 5.8, suggesting a valuation that may be considered expensive. Additionally, Pfizer has maintained a high dividend yield of 3.7%, which could be appealing to certain investors.
For those interested in further insights, you can explore more about Pfizer's financial trend performance.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
